Plaque Psoriasis Efficacy and Safety With Secukinumab
Launched by NOVARTIS PHARMACEUTICALS · Apr 1, 2015
Trial Information
Current as of July 07, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Main Inclusion Criteria:
- • 1. Chronic plaque-type psoriasis diagnosed for at least 6 months prior to Screening and candidate for systemic therapy.
- 2. Moderate to severe psoriasis at Baseline as evidenced by:
- • PASI ≥ 10 and
- • IGA mod 2011 score of 3 or higher (based on a scale of 0 to 4) and
- • BSA affected by plaque-type psoriasis of ≥ 10%.
- Main Exclusion Criteria:
- • 1. History of exposure to any biologic drug taken for the treatment of chronic plaque psoriasis or any other indication including but not limited to anti-tumor necrosis factor (TNF) alpha, anti interleukin (IL)12/23, or any anti-IL 17A or IL 17A receptor (IL 17AR) antibody.
- • 2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes.
- • 3. Forms of psoriasis other than chronic plaque-type (eg, pustular, erythrodermic and guttate psoriasis).
- • 4. Drug-induced psoriasis (ie, new onset or current exacerbation from beta-blockers, calcium channel inhibitors or lithium).
- • 5. Ongoing use of prohibited psoriasis treatments (eg, topical or systemic corticosteroids, ultraviolet (UV) therapy).
- • 6. Ongoing use of other non-psoriasis prohibited treatments. Washout periods detailed in the protocol have to be adhered to. All other prior non-psoriasis concomitant treatments must be at a stable dose as detailed in the protocol before initiation of study drug.
- • 7. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test (\> 5 mIU/mL).
- • 8. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study drug and for 16 weeks after stopping study drug.
- • 9. Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab therapy.
- • 10. Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal conditions) which, in the opinion of the Investigator, significantly immunocompromises the patient and/or places the patient at unacceptable risk for receiving an immunomodulatory therapy.
About Novartis Pharmaceuticals
Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Braunschweig, , Germany
Ulm, , Germany
Osijek, , Croatia
Berlin, , Germany
Sittard Geleen, , Netherlands
Zaragoza, , Spain
Vandoeuvre Les Nancy, , France
Hamburg, , Germany
Leipzig, , Germany
Basel, , Switzerland
Bruxelles, , Belgium
Saint Etienne, , France
Cordoba, Andalucia, Spain
Hospitalet De Llobregat, Barcelona, Spain
Santander, Cantabria, Spain
Baracaldo, Vizcaya, Spain
Zuerich, , Switzerland
Cannock, Staffordshire, United Kingdom
Lausanne, , Switzerland
Innsbruck, , Austria
Linz, , Austria
Gent, , Belgium
Liege, , Belgium
Muenster, , Germany
Sabadell, Barcelona, Spain
La Coruna, Galicia, Spain
Geneve, , Switzerland
Wien, , Austria
Frankfurt, , Germany
Stockholm, , Sweden
Uppsala, , Sweden
Petach Tikva, , Israel
Tel Aviv, , Israel
Madrid, , Spain
Hanau, , Germany
Muenchen, , Germany
Bordeaux Cedex, , France
Grenoble, , France
Bonn, , Germany
Salamanca, Castilla Y Leon, Spain
Santiago De Compostela, Galicia, Spain
Bilbao, Pais Vasco, Spain
La Laguna, Santa Cruz De Tenerife, Spain
Zagreb, , Croatia
Olomouc, , Czechia
Praha 10, , Czechia
Lille, , France
Canterbury, Kent, United Kingdom
Dijon, , France
Lubeck, , Germany
Montpellier Cedex 5, , France
Budapest, , Hungary
Debrecen, , Hungary
Kaposvar, , Hungary
Palermo, Pa, Italy
Roma, Rm, Italy
Sevilla, Andalucia, Spain
Valencia, Comunidad Valenciana, Spain
Tampere, , Finland
Alicante, Comunidad Valenciana, Spain
Goettingen, , Germany
Breda, Ck, Netherlands
Harrogate, , United Kingdom
Warszawa, , Poland
Barcelona, Catalunya, Spain
Brno, Czech Republic, Czechia
Badalona, Catalunya, Spain
Salford, Manchester, United Kingdom
Pamplona, Navarra, Spain
Kraków, , Poland
Pleven, , Bulgaria
Hellerup, , Denmark
Turku, , Finland
Cambridge, , United Kingdom
Stade, , Germany
Kosice, , Slovakia
Falun, , Sweden
Modena, Mo, Italy
Kazan, , Russian Federation
Plovdiv, , Bulgaria
Messina, Me, Italy
Nice, , France
Ramat Gan, , Israel
Jette, Brussel, Belgium
Larissa, Gr, Greece
Stara Zagora, , Bulgaria
Rouen, , France
Bolzano, Bz, Italy
Bratislava, , Slovakia
Dudley, West Midlands, United Kingdom
Szeged, , Hungary
Palma De Mallorca, Islas Baleares, Spain
Varna, , Bulgaria
Las Palmas De Gran Canaria, Las Palmas De G.C, Spain
Porto, , Portugal
Thessaloniki, Gr, Greece
Voorburg, , Netherlands
Stuttgart, , Germany
Toulouse Cedex, , France
Afula, , Israel
Praha, , Czechia
Augsburg, , Germany
Alcorcon, Madrid, Spain
Almere, , Netherlands
Leon, Castilla Y Leon, Spain
Murcia, , Spain
Athens, , Greece
Dresden, , Germany
Kaunas, Ltu, Lithuania
Schwerin, , Germany
Lodz, , Poland
Wroclaw, , Poland
Malmo, , Sweden
Vilnius, , Lithuania
Pommelsbrunn, , Germany
San Sebastian De Los Reyes, Madrid, Spain
Lublin, , Poland
Bochum, , Germany
Osnabrueck, , Germany
Daugavpils, Lva, Latvia
Ventspils, Lva, Latvia
Klaipeda, Ltu, Lithuania
Poznan, , Poland
Leeds, West Yorkshire, United Kingdom
Braga, , Portugal
Coimbra, , Portugal
Haifa, , Israel
Kecskemet, Bacs Kiskun, Hungary
Le Mans, , France
Geldrop, , Netherlands
Moscow, , Russian Federation
Arhus C, , Denmark
Sant Joan Despi, Barcelona, Spain
Sofia, Bgr, Bulgaria
Vila Nova De Gaia, , Portugal
Cliftonville, Northampton, United Kingdom
Olsztyn, , Poland
Rostov On Don Region, , Russian Federation
Chelyabinsk, , Russian Federation
Fuenlabrada, Madrid, Spain
Manises, Valencia, Spain
Bojnice, , Slovakia
Le Mans, , France
Ostrava Poruba, Czech Republic, Czechia
Saint Petersburg, , Russian Federation
Loverval, , Belgium
Ivanic Grad, , Croatia
Prague 8, Czech Republic, Czechia
Trevenans, , France
Duesseldorf, , Germany
Pecs, , Hungary
Riga, Lva, Latvia
Alkmaar, , Netherlands
Bergen Op Zoom, , Netherlands
Leiderdorp, , Netherlands
Ossy, , Poland
Leiria, , Portugal
Povazska Bystrica, , Slovakia
Svidnik, , Slovakia
Villajoyosa, Alicante, Spain
Granada, Andalucia, Spain
Malaga, Andalucia, Spain
Castellon, Comunidad Valenciana, Spain
Alzira, Valencia, Spain
Huesca, , Spain
Mallorca, , Spain
Pontevedra, , Spain
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Director
Novartis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials